Plunkett Research Online: Ophthotech Corp

OPHTHOTECH CORP (OPHT:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial grow.....



Ophthotech Corp
Ticker: OPHT
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 212 845-8200
Fax: 212 845-8250
Address: One Penn Plaza, 19th Floor
New York, NY 10119 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
ContactsDescription
David CarrollCFO/Senior VP/Treasurer
David GuyerChairman of the Board/Co-Founder/Director
See More
Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial grow.....See More See More

Auditor: Ernst & Young LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201620152014201320122011
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: